Aricept Evess

Donepezil HCl

Symptomatic treatment of mild to moderate & severe Alzheimer's dementia.

Adult/elderly Initially 5 mg once daily at bedtime, maintain for at least 1 mth. May be increased to 10 mg once daily, following 4-6 wk clinical assessment. If not adequately controlled, may be increased to 23 mg (one Aricept 23-mg FC tab).

May be taken with or without food: Place tab on the tongue. Allow to disintegrate before swallowing w/ or w/o water.

Hypersensitivity to donepezil HCl or piperidine derivatives. Pregnancy & lactation.

Exaggerated succinylcholine-type muscle relaxation during anaesth. Vagotonic effects on SA & AV nodes; syncopal episodes. May cause diarrhea, nausea, vomiting, wt loss. Patients w/ increased risk for developing ulcers eg, history of ulcer disease & those receiving concurrent NSAIDs. May cause bladder outflow obstruction. May exacerbate or induce extrapyramidal symptoms. History of asthma or obstructive pulmonary disease. Avoid concomitant use w/ other inhibitors of acetylcholinesterase, cholinergic system agonists or antagonists. Discontinue therapy if signs & symptoms of neuroleptic malignant syndrome or presents w/ unexplained high fever develop. Patients w/ predisposing/risk factors eg, prior history of muscular disorders, uncontrolled hypothyroidism, hepatic or renal impairment. Concomitant use w/ rhabdomyolysis-causing medications (eg, statins, antipsychotics, SSRIs/SNRIs). Dementia may affect ability to drive or operate machinery. Not recommended for childn.

Common cold; anorexia; hallucinations, agitation, aggressive behaviour; syncope, dizziness, insomnia; diarrhoea, vomiting, nausea, abdominal disturbance; rash, pruritus; muscle cramps; urinary incontinence; headache, fatigue, pain; accident.

Metabolism may be inhibited w/ ketoconazole & quinidine, CYP450, 3A4 & 2D6 inhibitors. Reduced clearance w/ CYP2D6 inhibitor. Increased rate of elimination w/ CYP2D6 & CYP3A4 inducers (eg, phenytoin carbamazepine, dexamethasone, rifampin & phenobarb). May interfere w/ the activity of anticholinergics. Synergistic effect w/ succinylcholine, similar neuromuscular blocking agents or cholinergic agonists eg, bethanechol.

Neurodegenerative Disease Drugs

N06DA02 - donepezil ; Belongs to the class of anticholinesterases. Used in the management of dementia.

POM